Literature DB >> 25024675

Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Pulmonary Exacerbation in a Pediatric Cystic Fibrosis Patient.

Leah Molloy1, Ashley Hall Snyder2, Ruma Srivastava3, Michael J Rybak4, Eric McGrath5.   

Abstract

Ceftaroline, an advanced generation cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA), may present a new therapeutic alternative for treating lung infections among patients with cystic fibrosis. We report a case of ceftaroline therapy in a pediatric patient with cystic fibrosis, whose dose was increased from 9.7 mg/kg/dose every 12 hours to 10.8 mg/kg/dose every 8 hours by using pharmacokinetic analyses.

Entities:  

Keywords:  ceftaroline; cystic fibrosis; pediatrics; pharmacodynamics; pharmacokinetics

Year:  2014        PMID： 25024675      PMCID： PMC4093667          DOI： 10.5863/1551-6776-19.2.135

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN： 1551-6776


  14 in total

1.  Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy.

Authors:  Tony T Ho; Jose Cadena; Lindsey M Childs; Miguel Gonzalez-Velez; James S Lewis
Journal:  J Antimicrob Chemother       Date:  2012-02-06       Impact factor: 5.790

2.  Renal function in pediatric cystic fibrosis patients in the first decade of life.

Authors:  Chanel Prestidge; Mark A Chilvers; A George F Davidson; Eva Cho; Vanessa McMahon; Colin T White
Journal:  Pediatr Nephrol       Date:  2010-12-29       Impact factor: 3.714

Review 3.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

4.  Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis.

Authors:  Elliott C Dasenbrook; William Checkley; Christian A Merlo; Michael W Konstan; Noah Lechtzin; Michael P Boyle
Journal:  JAMA       Date:  2010-06-16       Impact factor: 56.272

5.  Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.

Authors:  K Kosowska-Shick; P L McGhee; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2010-03-01       Impact factor: 5.191

6.  Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases.

Authors:  Arnold Louie; Mariana Castanheira; Weiguo Liu; Caroline Grasso; Ronald N Jones; Gregory Williams; Ian Critchley; Dirk Thye; David Brown; Brian Vanscoy; Robert Kulawy; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

Review 7.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

8.  Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis.

Authors:  M D Reed; R C Stern; J S Bertino; C M Myers; T S Yamashita; J L Blumer
Journal:  J Pediatr       Date:  1984-02       Impact factor: 4.406

Review 9.  Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis.

Authors:  D J Touw
Journal:  Pharm World Sci       Date:  1998-08

Review 10.  Update on the epidemiology and management of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, in patients with cystic fibrosis.

Authors:  Anne Stone; Lisa Saiman
Journal:  Curr Opin Pulm Med       Date:  2007-11       Impact factor: 3.155
View more
  2 in total

1.  Recovery of a 10-year-old girl from methicillin-resistant Staphylococcus aureus sepsis in response to low-dose ceftaroline treatment.

Authors:  Stefan Borgmann; Beate Rieß; Thomas von Wernitz-Keibel; Matthias Bühler; Franziska Layer; Birgit Strommenger
Journal:  Ther Clin Risk Manag       Date:  2016-05-11       Impact factor: 2.423

Review 2.  Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application.

Authors:  Juwon Yim; Leah M Molloy; Jason G Newland
Journal:  Infect Dis Ther       Date:  2016-12-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.